Baxter International Inc. (BAX) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

Earnings Reports

• Baxter (BAX) Q2 2026: Drug Compounding Delivers Double-Digit Growth, Offsetting Margin Compression
  July 30, 2026
• Baxter (BAX) Q4 2025: Gross Margin Drops 900bps as Mix, Tariffs, and Inventory Weigh on Turnaround
  June 15, 2026
• Baxter (BAX) Q1 2026: Free Cash Flow Swings $297M, Underscoring Turnaround Traction
  April 30, 2026
• Baxter (BAX) Q3 2025: Dividend Slashed to $0.01, Unlocking $300M for Deleveraging
  October 30, 2025
• Baxter (BAX) Q2 2025: Operational Sales Growth Cut to 3% as Novum Pause and Fluid Conservation Extend Headwinds
  July 31, 2025
• Baxter (BAX) Q1 2025: Tariff Exposure Hits $70M, Margin Expansion Still on Track
  July 04, 2025
• Baxter (BAX) Q3 2024: North Cove Disruption Drives $200M Q4 Sales Hit, Margin Recovery Hinges on Execution
  November 08, 2024
• Baxter (BAX) Q2 2024: Margin Expands 80bps as Novum and Pharma Drive 4% Growth
  August 06, 2024
• Baxter (BAX) Q1 2024: Pharmaceuticals Surge 11% as Margin Programs Lift Operating Leverage
  May 02, 2024
• Baxter (BAX) Q4 2023: $2.8B Debt Paydown Reshapes Capital Allocation Ahead of Kidney Care Spin
  February 08, 2024

Browse all companies